ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
Pipeline
ImmuPharma is a biopharmaceutical company that specialises in the usage and development of biopolymers, specifically peptides.
Our late-stage to preclinical pipeline is focused on two core therapeutic areas; autoimmunity & inflammation and anti-infectives.
*Phase 2/3 adaptive trial becomes a pivotal trial for filing
Our core therapeutic areas
The P140 platform
LUPUZORTM for Lupus
P140 for CIDP
BioAMB
for systemic fungal infections
BioCIN
for severe bacterial infections
Key progress
Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce ...